JBI-589

JBI-589 is a non-covalent PAD4 isoform-selective inhibitor with oral bioavailability. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors. JBI-589 can be used in cancer research[1][2].

Product Specifications

CAS Number

[2308504-22-3]

UNSPSC

12352005

Target

Protein Arginine Deiminase

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/jbi-589.html

Concentration

10mM

Purity

99.75

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(N1C(C=C(C=C1)C(N2C[C@@H](CCC2)N)=O)=N3)=C3C4=CC5=CC=CC=C5N4CC6=CC=C(C=C6)F

Molecular Formula

C29H28FN5O

Molecular Weight

481.56

References & Citations

[1]Deng H, et al. A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression. Cancer Res. 2022 Oct 4;82 (19) :3561-3572.|[2]Gajendran C, et al. Alleviation of arthritis through prevention of neutrophil extracellular traps by an orally available inhibitor of protein arginine deiminase 4. Sci Rep. 2023 Feb 23;13 (1) :3189.